COMPARATIVE ANALYSIS OF BRONCHODILATORY POTENTIAL OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST WITH A BETA 2 RECEPTOR AGONIST
NORTHWEST JOURNAL OF MEDICAL SCIENCES · 2022
DOI: 10.69723/njms.01.03.0279 ↗Abstract
Background : PPAR-γ is also expressed in the lung epithelium, submucosa, and airway smooth muscle. PPAR-δ is broadly expressed with a regulatory role in energy homeostasis, thermogenesis, keratinocyte proliferation and differentiation. PPAR-α and PPAR-γ have been identified as important immunomodulators having potential as novel anti-inflammatory targets for airway diseases. Thiazolidinediones including Pioglitazone and Rosiglitazone are agonists of the receptor and therefore may possess bronchodilating properties. Salbutamol, a beta 2 agonist being used as a bronchodilator has a number of adverse effects based on which the main idea for this study was postulated. Methodology : An experimental study of one week was carried out at animal house of Northwest School of Medicine, on a total of 24 guinea pigs randomly divided into four groups as Group 1 (Histamine control group), Group 2 (Histamine + Salbutamol), Group 3 (Histamine + Rosiglitazone) and Group 4 (Histamine + Pioglitazone). An isometric volume transducer was used to measure the drug effect on histamine induced contractions of the smooth muscles. Comparisons were made by one way ANOVA with a Tukey's post hoc test. Results : Both Pioglitazone and rosiglitazone significantly reduced the histamine induced contractions with an efficacy equal to salbutamol. Between the two, Pioglitazone produced more potent effect as compared to rosiglitazone. Conclusion : Thiazolidinediones significantly reduce histamine induced smooth muscle contractions of, which is comparable to the effect of salbutamol. Key words : PPAR- γ, Thiazolidinediones, Beta 2 receptor, Salbutamol, Histamine
EUVIMED